Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives $3.67 Consensus Price Target from Brokerages

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) has earned an average rating of "Hold" from the five research firms that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $3.67.

A number of analysts have issued reports on the stock. Needham & Company LLC reiterated a "hold" rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 3rd. Piper Sandler reduced their price objective on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. HC Wainwright reissued a "buy" rating and set a $4.00 target price on shares of Lexicon Pharmaceuticals in a research report on Friday, March 28th. StockNews.com began coverage on shares of Lexicon Pharmaceuticals in a research report on Monday, April 21st. They issued a "sell" rating on the stock. Finally, Leerink Partners restated a "market perform" rating and set a $1.00 target price (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research note on Tuesday, March 4th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Straight Path Wealth Management bought a new stake in Lexicon Pharmaceuticals in the first quarter valued at approximately $29,000. Bayesian Capital Management LP bought a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at $31,000. Wealth Enhancement Advisory Services LLC acquired a new stake in Lexicon Pharmaceuticals during the 1st quarter worth $32,000. RPO LLC bought a new position in Lexicon Pharmaceuticals during the fourth quarter worth about $33,000. Finally, Renaissance Technologies LLC acquired a new position in Lexicon Pharmaceuticals in the fourth quarter valued at about $38,000. 74.70% of the stock is currently owned by institutional investors.

Lexicon Pharmaceuticals Price Performance

Shares of LXRX traded down $0.02 during mid-day trading on Friday, hitting $0.71. The company's stock had a trading volume of 2,080,233 shares, compared to its average volume of 6,481,675. Lexicon Pharmaceuticals has a fifty-two week low of $0.28 and a fifty-two week high of $2.45. The stock has a market capitalization of $174.34 million, a price-to-earnings ratio of -0.95 and a beta of 1.02. The firm has a 50-day moving average price of $0.49 and a 200 day moving average price of $0.82. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last released its quarterly earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The business had revenue of $26.55 million during the quarter, compared to analyst estimates of $6.48 million. On average, research analysts predict that Lexicon Pharmaceuticals will post -0.66 EPS for the current fiscal year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.